FDA Requires Design Changes To Fentanyl Patches

FDA Requires Design Changes To Fentanyl Patches

By |2019-05-29T17:05:12+00:00September 26th, 2013|Blog Posts in 2013, News Blog|0 Comments

The FDA recently posted a press release regarding a voluntary global correction of Samaritan® 300/300P PAD public access defibrillators made by HeartSine Technologies, Ltd. According to the press release, issues with power management in defibrillators made prior to December 2010 may prevent these devices from functioning properly or at all during a cardiac event. The press release includes instructions and information regarding corrective measures offered by the company.

Source: FDA – http://www.fda.gov/Safety/Recalls/ucm368535.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

About the Author:

Leave A Comment